#ASH20 Loxo and Eli Lilly show off PhI/II data for their BTK inhibitor in two blood cancers
ASH is back and Loxo is primed and ready to present new data that they think will be quite exciting.
The Lilly-owned company is announcing results from a Phase I/II trial on its LOXO-305 program, and Saturday afternoon they detailed data in patients with mantle cell lymphoma (MCL) and other non-Hodgkin lymphomas. And Monday morning, Loxo added to their data portfolio with results from the program in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.